ANIK
Anika Therapeutics, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $4.3M | Q1 FY2026 | — |
| International OA Pain Management revenue | $8.9M | Q1 FY2026 | — |
| U.S. Integrity procedure growth | 35% | Q1 FY2026 | — |
| U.S. Integrity revenue | $1.8M | Q1 FY2026 | — |
| commercial channel revenue growth | 12% | first quarter call | — |
| OEM channel revenue growth | 14% | first quarter call | — |
| total Integrity cases to date | 3,000 | first quarter call | — |
| U.S. procedures growth (Integrity) | 35% | first quarter call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANIK
this stock
Anika Therapeutics, Inc.
|
$210.49M | +64.6% | +6.1% | — | 3.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$54.77B | +7.3% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$49.13B | +1.1% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.48B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANIK | -1.7% | +10.6% | +68.5% | +8.1% | +64.6% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -1.6% | +10.6% | +59.5% | +7.6% | +54.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.